What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?
- 31 August 2012
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 48 (12), 1781-1790
- https://doi.org/10.1016/j.ejca.2012.03.016
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2Journal of Clinical Oncology, 2010
- Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trialAnnals of Oncology, 2009
- Issues in Using Progression-Free Survival When Evaluating Oncology ProductsJournal of Clinical Oncology, 2009
- Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203Journal of Clinical Oncology, 2006
- Chemotherapy with Preoperative Radiotherapy in Rectal CancerThe New England Journal of Medicine, 2006
- Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal CancerThe New England Journal of Medicine, 2001
- Improved Survival with Preoperative Radiotherapy in Resectable Rectal CancerThe New England Journal of Medicine, 1997
- Analysis of local recurrence rates after surgery alone for rectal cancerInternational Journal of Colorectal Disease, 1995
- Effective Surgical Adjuvant Therapy for High-Risk Rectal CarcinomaThe New England Journal of Medicine, 1991
- Preoperative Radiotherapy as Adjuvant Treatment in Rectal CancerAnnals of Surgery, 1988